2Bakken R, van Walraven AM, Egeland T, et al. Donor commitment and patient needs. Bone Marrow Transplant. 2004;33(2):225-230.
3Food and Drug Administration, HHS. Human cells, tissues, and cellular and tissue-based products; donor screening and testing, and related labeling. Interim final rule; opportunity for public comment. Fed Regist. 2005;70(100):29949-29952.
4Foundation for the Accreditation of Cellular Therapy. Standards for Hematopoietic Progenitor Cell Collection, Processing & Transplantation. 2nd ed. Omaha: Foundationfor the Accreditation of Cellular Therapy (FACT), 2004.
5National Marrow Donor Program. National Marrow Donor Program Standards. 18th Edition. Minneapolis: National Marrow Donor Program, 2002.
6Lau GK, Liang R, Lee CK, et al. Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive.J Infect Dis. 1998; 178(6):1585-1591.
7Lau GK, Lie AK, Kwong YL,et al. A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation. Blood. 2000;96(2): 452-458.
8Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001 ;98(7):2043-2051.
9Andrykowski MA. Psychiatric and psychosocial aspects of bone marrow transplantation. Psychosomatics. 1994;35(1): 13-24.
10Barbarin OA, Sargent JR, Sahler O J, et al. Sibling Adaptation to Childhood Cancer Collaborative Study: Parental views of pre- and postdiagnosis adjustment of siblings of children with cancer. Journal of Psychosocial Oncology. 1995; 13:1-20.
